Farmas USA

que pesao el tio!!!!!
enesimo post que saca asi, cada vez que pierde los 7 NVAX.

Check out @YoungMula message on StockTwits http://stocktwits.com/YoungMula/message/45238684

OCAT

El proceso de oferta y compra parece que va como sigue por si a alguien le interesa:

You will get a tender offer presented to you from the company via your broker within the week. You can either accept or deny. Once the merger goes through, money will be deposited in your account. We won't vote unless Astellas fails to get the required percentage of shares.

Felicidades a todos los metidos en OCAT. Ahora sí que puedo decir que haberlas hallas. La primera que veo en el foro. Y espero que no sea la última y esta vez me pille dentro.

Ya tenemos emoticono para cuando nos toque :))

ARNA

Arena Pharmaceuticals Reports Third Quarter 2015 Financial Results and Provides Corporate Update

http://www.prnewswire.com/news-releases/arena-pharmaceuticals-reports-third-quarter-2015-financial-results-and-provides-corporate-update-300176076.html

-- Conference Call and Webcast Scheduled for Today at 5:00 p.m. Eastern Time --

SAN DIEGO, Nov. 10, 2015 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today reported financial results for the third quarter ended September 30, 2015, and provided a corporate update.

"On October 27, we announced a plan to improve efficiencies and reduce costs as we chart a new course for Arena with our refocusing effort," said Harry F. Hixson, Jr., Arena's interim Chief Executive Officer. "As we head into 2016, we intend to continue to implement this plan to be sure we are taking full advantage of our key strengths in a strategic, optimized manner."

Third Quarter and Recent Developments

Corporate Update

Announced plans to improve efficiencies and reduce costs as it focuses on the advancement of its research and development priorities. As part of this initiative, Arena reduced its US workforce by approximately 80 employees or 35%, which is expected to reduce annualized cash expenditures for personnel by approximately $11.0 million. Arena plans to implement additional cost control measures to further reduce its expenditures, including reductions at its Swiss manufacturing facility, Arena Pharmaceuticals GmbH.

Research and Development Update

Announced the initiation of a Phase 2 proof-of-concept clinical trial of APD334, an oral Sphingosine 1-Phosphate Subtype 1 receptor modulator for autoimmune diseases, being studied in this trial for the treatment of ulcerative colitis.
Announced the initiation of a Phase 1b multiple-ascending dose clinical trial of APD371, a selective and potent agonist of the cannabinoid 2 receptor.
Axovant Sciences Ltd. acquired all of Roivant Sciences Ltd.'s rights to nelotanserin, an inverse agonist of the serotonin 2A receptor internally discovered by Arena. Arena previously granted Roivant, Axovant's parent company, exclusive worldwide rights to develop and commercialize nelotanserin under a Development, Marketing and Supply Agreement. Axovant announced that it intends to initiate two Phase 2 clinical trials with nelotanserin in the first quarter of 2016, with the first trial in patients with either dementia with Lewy bodies, or Parkinson's disease dementia who suffer from visual hallucinations, and the second trial in dementia with Lewy bodies patients experiencing REM Behavior Disorder.

BELVIQ® (lorcaserin HCl) Update

Eisai acknowledged difficulties in the US anti-obesity market and announced plans to focus on patients and physicians in certain areas of the US where there is insurance coverage and a need for treatment options.
IMS Health estimates that approximately 157,000 prescriptions for BELVIQ were filled in the US in the third quarter of 2015, representing growth in total prescriptions of approximately 9.8% compared to the same quarter of last year and a decrease of 14.4% compared to the previous quarter.
Ildong Pharmaceutical Co., Ltd., estimates that approximately 2.1 million tablets of BELVIQ were prescribed in South Korea in the third quarter of 2015, which equates to approximately 34,400 one-month prescriptions, representing growth in total prescriptions of approximately 18.6% compared to the previous quarter.
Announced that the US Patent and Trademark Office granted Arena US Patent No. 9,169,213, entitled "Method of Weight Management," covering BELVIQ for chronic weight management. The patent is based on the discovery that achieving 5% weight loss with BELVIQ by Week 12 is a strong predictor of responses in weight loss at Week 52 of treatment.

Third Quarter 2015 Financial Results

Revenues totaled $9.1 million, including $4.9 million in net product sales of BELVIQ.
Research and development expenses totaled $22.1 million.
General and administrative expenses totaled $9.0 million.
Net loss was $26.4 million, or $0.11 per share.
At September 30, 2015, cash and cash equivalents totaled $181.3 million and approximately 242.4 million shares of common stock were outstanding.

Scheduled Conference Call and Webcast

Arena will host a conference call and webcast today at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) to provide a corporate update and report third quarter 2015 financial results. The conference call may be accessed by dialing 877.643.7155 for domestic callers and 914.495.8552 for international callers. Please specify to the operator that you would like to join the "Arena Pharmaceuticals' Third Quarter 2015 Financial Results and Corporate Update Conference Call." The conference call will be webcast live under the investor relations section of Arena's website at www.arenapharm.com, and will be archived there for 30 days following the call. Please connect to Arena's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

ARNA

Arena Pharmaceuticals beats by $0.02, revenue in-line

Novavax to Present at the Stifel 2015 Healthcare Conference

http://ir.novavax.com/phoenix.zhtml?c=71178&p=irol-newsArticle&ID=2111200

 

GAITHERSBURG, Md., Nov. 10, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that Barclay “Buck” Phillips, SVP, Chief Financial Officer and Treasurer, will present at the Stifel 2015 Healthcare Conference.

Conference details are as follows:

Date: Tuesday, November 17, 2015
Time: 4:30 p.m. US Eastern Time
Location: New York Palace Hotel, New York City
Live webcast: http://www.veracast.com/webcasts/stifel/healthcare2015/86112760876.cfm

A ver, Sres., he pillado poquillas NVAX a 7,01 en after....
A ver si remontan el vuelo....

NVAX